GlassScriptPhysician profile
Joseph George Kamel
NPI 1003304759
$11,012.66
in general payments reported to CMS, 2019-2025
24 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $2,015 · 2021: $43.01 · 2022: $126 · 2023: $1,283 · 2024: $5,360 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Consulting Fee: $3,250 · Education: $89.00 · Travel and Lodging: $67.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,203.01 |
| Consulting Fee | $3,250.00 |
| Education | $89.00 |
| Travel and Lodging | $67.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,755.03 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $2,335.15 | 2020-2024 | Sotyktu |
| Abbvie INC. | $1,293.92 | 2019-2025 | |
| Amgen INC. | $684.43 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $515.64 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $475.99 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $370.52 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $316.22 | 2023-2025 | |
| Pfizer INC. | $218.91 | 2023-2024 | |
| Janssen Biotech, INC. | $208.95 | 2025 | Tremfya |
| Leo Pharma INC. | $180.38 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $160.80 | 2023-2025 | Winlevi |
| Novartis Pharmaceuticals Corporation | $77.63 | 2023-2025 | |
| Organogenesis INC. | $72.53 | 2025 | Simplimax |
| Blueprint Medicines Corporation | $55.36 | 2024 | Ayvakit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $46.95 | 2025 | Grafix Pl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.96 | 2024 | Caplyta |
| Verrica Pharmaceuticals INC. | $43.23 | 2023-2024 | Ycanth |
| Lilly USA, LLC | $34.29 | 2025 | Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $31.41 | 2024-2025 | Zoryve |
| Organon LLC | $28.87 | 2025 | Vtama |
| Fresenius Kabi USA, LLC | $23.50 | 2025 | |
| Kyowa Kirin, INC. | $19.94 | 2025 | |
| Incyte Corporation | $18.05 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.